Market Cap 805.68M
Revenue (ttm) 403.14M
Net Income (ttm) -22.68M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 68.26
Profit Margin -5.63%
Debt to Equity Ratio -0.50
Volume 12,197,600
Avg Vol 12,174,937
Day's Range N/A - N/A
Shares Out 257.41M
Stochastic %K 96%
Beta 0.91
Analysts Hold
Price Target $2.91

Company Profile

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 734 887 3903
Address:
3891 Ranchero Drive, Suite 150, Ann Arbor, United States
maxhappy
maxhappy May. 13 at 11:10 PM
$ESPR I might finally be getting in trouble for using bad language among other things. My last post trashing Sheldung and co may have been take down If I am removed from Stocktwits, just know that I am still here. I have always hated and not trusted Sheldung, but I thought our drug was so good that he couldn't screw it up for too long. I was wrong. I hate the BOD . I hate management. I hate all the Sheldung cheerleaders. And DJ should show himself
0 · Reply
Lskynrd1
Lskynrd1 May. 13 at 10:50 PM
$ESPR How they get away this boggles the mind they have a fudicary duty to act in the best interest of the company and shareholders and they did the opposite
1 · Reply
Shar1ah
Shar1ah May. 13 at 8:59 PM
$ESPR Why sell rights and royalties at a discount, buy another biotech, if you are going to sell the company? The answer is obvious, for 5-6 years dozens of such decisions, if someone goes to court, look, games with shorts, as in Sheldon's statements that clear went great, a large seller came out and the company gave curved research data, which rolled the share, and then gave normal figures, but the shares were no longer recovered, and the short grew before his statement, well, in fact, anyone will find all these mistakes
0 · Reply
Shar1ah
Shar1ah May. 13 at 8:53 PM
$ESPR I'm almost sure that they wanted to bankrupt the company, just a stock from the previous CEO, and the drug sold itself, there was a lot of information that the company's sellers are sitting and playing ps, instead of working. Despite their efforts, it didn't work out to go bankrupt and had to do it like this
0 · Reply
Shar1ah
Shar1ah May. 13 at 8:50 PM
$ESPR Can I ask you a question? There has been fraud in this company for 5 years, if someone didn't follow, it doesn't mean that everything was fair. And these 5 years Sheldon was re-elected without any problems, so leave your dreams, everything is decided here, I wrote here at least 5 times with calls to write to the SEC, but the locals said that everything is fine here, and I'm offended
0 · Reply
BonprixUltimateGuardians
BonprixUltimateGuardians May. 13 at 8:48 PM
0 · Reply
JasonZemanskyPhD
JasonZemanskyPhD May. 13 at 8:39 PM
$ESPR The new logo of ESPR .
1 · Reply
NEWBIGTECH
NEWBIGTECH May. 13 at 8:33 PM
$ESPR I asked Grok. if DAIICHI Could, would make a Bid.
0 · Reply
NEWBIGTECH
NEWBIGTECH May. 13 at 8:13 PM
1 · Reply
NEWBIGTECH
NEWBIGTECH May. 13 at 8:05 PM
$ESPR DID YOU SEE $SLS today. WOW.
0 · Reply
Latest News on ESPR
Esperion downgraded to Hold from Buy at Needham

2026-05-04T19:10:14.000Z - 9 days ago

Esperion downgraded to Hold from Buy at Needham


Esperion downgraded to Hold from Buy at Jefferies

2026-05-01T19:26:03.000Z - 12 days ago

Esperion downgraded to Hold from Buy at Jefferies


Esperion downgraded to Neutral from Buy at H.C. Wainwright

2026-05-01T15:12:52.000Z - 12 days ago

Esperion downgraded to Neutral from Buy at H.C. Wainwright


Esperion to be Acquired by ARCHIMED

May 1, 2026, 7:00 AM EDT - 12 days ago

Esperion to be Acquired by ARCHIMED


Esperion showcases new data from CLEAR Outcomes trial

2026-03-30T13:21:46.000Z - 6 weeks ago

Esperion showcases new data from CLEAR Outcomes trial


Esperion price target raised to $5 from $4 at Citizens

2026-03-13T09:36:20.000Z - 2 months ago

Esperion price target raised to $5 from $4 at Citizens


Esperion Therapeutics Earnings Call Transcript: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 2 months ago

Esperion Therapeutics Earnings Call Transcript: Q4 2025


Esperion reports Q4 EPS 22c, consensus 28c

2026-03-10T10:06:52.000Z - 2 months ago

Esperion reports Q4 EPS 22c, consensus 28c


Esperion Therapeutics Transcript: M&A announcement

Mar 3, 2026, 8:00 AM EST - 2 months ago

Esperion Therapeutics Transcript: M&A announcement


Esperion signs definitive acquisition of Corstasis Therapeutics

2026-03-03T11:05:38.000Z - 2 months ago

Esperion signs definitive acquisition of Corstasis Therapeutics


Esperion reaches settlement agreement with Alkem

2026-02-17T13:16:28.000Z - 3 months ago

Esperion reaches settlement agreement with Alkem


Esperion Therapeutics Transcript: KOL Event

Nov 11, 2025, 2:00 PM EST - 6 months ago

Esperion Therapeutics Transcript: KOL Event


Esperion Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:00 AM EST - 6 months ago

Esperion Therapeutics Earnings Call Transcript: Q3 2025


Esperion Announces Pricing of Public Offering of Common Stock

Oct 7, 2025, 9:29 PM EDT - 7 months ago

Esperion Announces Pricing of Public Offering of Common Stock


Esperion Announces Proposed Public Offering of Common Stock

Oct 7, 2025, 4:01 PM EDT - 7 months ago

Esperion Announces Proposed Public Offering of Common Stock


Esperion Therapeutics Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Esperion Therapeutics Earnings Call Transcript: Q2 2025


Esperion Appoints Craig Thompson to Board of Directors

Jul 1, 2025, 8:06 AM EDT - 11 months ago

Esperion Appoints Craig Thompson to Board of Directors


Esperion Therapeutics Earnings Call Transcript: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q1 2025


Esperion Therapeutics Transcript: Status Update

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Esperion Therapeutics Transcript: Status Update


Esperion Appoints Robert E. Hoffman to Board of Directors

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Esperion Appoints Robert E. Hoffman to Board of Directors


Esperion Therapeutics Earnings Call Transcript: Q4 2024

Mar 4, 2025, 8:00 AM EST - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q4 2024


Esperion Therapeutics Transcript: KOL Event

Jan 22, 2025, 12:30 PM EST - 1 year ago

Esperion Therapeutics Transcript: KOL Event


Esperion Announces $210 Million Convertible Debt Financing

Dec 13, 2024, 6:00 AM EST - 1 year ago

Esperion Announces $210 Million Convertible Debt Financing


Esperion Therapeutics Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q3 2024


Esperion Therapeutics Earnings Call Transcript: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q2 2024


maxhappy
maxhappy May. 13 at 11:10 PM
$ESPR I might finally be getting in trouble for using bad language among other things. My last post trashing Sheldung and co may have been take down If I am removed from Stocktwits, just know that I am still here. I have always hated and not trusted Sheldung, but I thought our drug was so good that he couldn't screw it up for too long. I was wrong. I hate the BOD . I hate management. I hate all the Sheldung cheerleaders. And DJ should show himself
0 · Reply
Lskynrd1
Lskynrd1 May. 13 at 10:50 PM
$ESPR How they get away this boggles the mind they have a fudicary duty to act in the best interest of the company and shareholders and they did the opposite
1 · Reply
Shar1ah
Shar1ah May. 13 at 8:59 PM
$ESPR Why sell rights and royalties at a discount, buy another biotech, if you are going to sell the company? The answer is obvious, for 5-6 years dozens of such decisions, if someone goes to court, look, games with shorts, as in Sheldon's statements that clear went great, a large seller came out and the company gave curved research data, which rolled the share, and then gave normal figures, but the shares were no longer recovered, and the short grew before his statement, well, in fact, anyone will find all these mistakes
0 · Reply
Shar1ah
Shar1ah May. 13 at 8:53 PM
$ESPR I'm almost sure that they wanted to bankrupt the company, just a stock from the previous CEO, and the drug sold itself, there was a lot of information that the company's sellers are sitting and playing ps, instead of working. Despite their efforts, it didn't work out to go bankrupt and had to do it like this
0 · Reply
Shar1ah
Shar1ah May. 13 at 8:50 PM
$ESPR Can I ask you a question? There has been fraud in this company for 5 years, if someone didn't follow, it doesn't mean that everything was fair. And these 5 years Sheldon was re-elected without any problems, so leave your dreams, everything is decided here, I wrote here at least 5 times with calls to write to the SEC, but the locals said that everything is fine here, and I'm offended
0 · Reply
BonprixUltimateGuardians
BonprixUltimateGuardians May. 13 at 8:48 PM
0 · Reply
JasonZemanskyPhD
JasonZemanskyPhD May. 13 at 8:39 PM
$ESPR The new logo of ESPR .
1 · Reply
NEWBIGTECH
NEWBIGTECH May. 13 at 8:33 PM
$ESPR I asked Grok. if DAIICHI Could, would make a Bid.
0 · Reply
NEWBIGTECH
NEWBIGTECH May. 13 at 8:13 PM
1 · Reply
NEWBIGTECH
NEWBIGTECH May. 13 at 8:05 PM
$ESPR DID YOU SEE $SLS today. WOW.
0 · Reply
Gary9912
Gary9912 May. 13 at 7:48 PM
$ESPR is this true? Not enough time? https://x.com/inshatters1/status/2054188306422776087?s=46&t=0qGPcTfX8as0XYMijymapw
1 · Reply
meistermell
meistermell May. 13 at 5:12 PM
$ESPR $GERN and $XERS two recommendations on our end for those looking for what could be next. And $SLS
2 · Reply
meistermell
meistermell May. 13 at 4:19 PM
$ESPR what competition is dingbat talking about, BA has zero competition besides the generics on 2040. All other lipid lowering drugs do not work.
3 · Reply
OldManLogan
OldManLogan May. 13 at 2:50 PM
$ESPR This is sincerely my take as well. Many of the things that didn't make sense before only make sense once you assume that Sheldon and Ben made a concerted effort to tank the share price in order to get a lowball deal through. Frankly, while absolutely disgusting, it's impressive that they could tank the share price at the same time that ESPR got included in the guidelines in a major way... that's why they promised then backed off on profitability; why they said that Japan was killing it at first but then said 'don't expect too much from Japan'. That's why they bought Enbumyst after promising not to go out and buy companies. It was all an effort to create HUGE phantom premium so that a disgustingly low offer could succeed. I hope for the remaining longs that another bid shows up, but Sheldon and Ben and very incentivized to stop that from happening. Cheers to longs.
2 · Reply
wRsYUeX
wRsYUeX May. 13 at 1:26 PM
0 · Reply
biotech_sellout
biotech_sellout May. 13 at 1:18 PM
$ESPR AWESOME NEWS TODAY! IT SHOULD DEFINITELY POP THE STOCK TO $3.16!
0 · Reply
kemah
kemah May. 13 at 1:04 PM
$ESPR ARCHIMED take-private (May 1) — big bank analyst reactions: *2/5 top analysts commented & adjusted: • Dennis Ding (Jefferies): Downgraded Buy→Hold, PT to $3.28 (from $5). “Good outcome” but no upside left beyond $3.16 offer due to coming competition. • Kristen Kluska (Cantor): Downgraded to Neutral, PT $3.16. Deal “appears low” vs ~$1.5B peak sales potential. *Other 3 silent: Zemansky (BofA), Choi (GS), Fye (JPM). Stock ~$3.16 + CVR. Close Q3 expected. Why no auction process? Why this single covert PE deal? Shareholders deserve full transparency on the rushed process.
0 · Reply
refinedindividual
refinedindividual May. 13 at 12:40 PM
$ESPR Where is the voting material for the 5/28 meeting? How can we not elect directors so this LOUSY merger dies
1 · Reply
TripleWitch
TripleWitch May. 13 at 12:29 PM
$ESPR this company is being stolen by CRIMINALS…. 🗑️ 🔥 🗑️
0 · Reply
MrPeter
MrPeter May. 13 at 12:01 PM
$ESPR and now they are issuing press releases for a new study?
1 · Reply
Stock765
Stock765 May. 13 at 11:33 AM
$ESPR Esperion accepted a low bowl offer and now you'r sitting in your small, dark boffer - don'r worry, be happy! Would Sheldon really want to sell the shares he earned for his life's work so cheaply? I seriously doubt it.
1 · Reply